What is Ocular Therapeutix's change in accrued liabilities?

Ocular Therapeutix (OCUL) reported change in accrued liabilities of -$8.44M in Q1 2026.

How has Ocular Therapeutix's change in accrued liabilities changed year-over-year?

Ocular Therapeutix's change in accrued liabilities decreased by 64.1% year-over-year, from -$5.15M to -$8.44M.

What does change in accrued liabilities mean?

Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.

Ocular Therapeutix OCUL Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Tarsus Pharmaceuticals, Inc.TARS

-$9.25M-57.0%

Kodiak Sciences IncKOD

$4.56M+93.5%

PBH

Prestige Consumer HealthcarePBH

$2.44M-35.5%

Arcutis Biotherapeutics, Inc.ARQT

$20.77M+9,805%

Axsome TherapeuticsAXSM

$17.23M+2,006%

LQD

Liquidia CorporationLQDA

$14.53M+402%

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's change in accrued liabilities?: Ocular Therapeutix (OCUL) reported change in accrued liabilities of -$8.44M in Q1 2026.
How has Ocular Therapeutix's change in accrued liabilities changed year-over-year?: Ocular Therapeutix's change in accrued liabilities decreased by 64.1% year-over-year, from -$5.15M to -$8.44M.
What does change in accrued liabilities mean?: Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.